USP disintegration test pending
Each 4 mg ondansetron orally disintegrating tablet, USP for oral administration contains 4 mg ondansetron base
Ondansetron AN ODT is available as orally disintegrating tablets containing 4 mg and 8 mg ondansetron
Each 8-mg ZOFRAN ODT orally disintegrating tablet for oral administration contains 8 mg ondansetron base
Ondansetron, orally disintegrating tablet (Zofran, Zofran ODT, Zuplenz) is a medication prescribed to prevent vomiting and nausea caused by chemotherapy, a cancer treatment
77, No
One 8 mg ondansetron orally disintegrating tablet should be administered twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy
Ondansetron Orally Disintegrating Tablets USP, 4 mg are white to off-white, round tablets debossed with ‘5’ on one side and ‘E’ on the other side with an embossed circular edge
Dosage reduction may be necessary for severe liver disease
One 8 mg ondansetron orally disintegrating tablet should be administered twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy
READ MORE
4 Special Warnings and Precautions for Use)